Table 1.

Quality assessment

Study	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10	Quality score
Abdollahpour et al.   31	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	9/10
Abbasi et al.   30	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	NA	Yes	8/9
Abdollahpour et al.   34	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	10/10
Shivappa et al.   21	Yes	Yes	No	yes	Yes	Yes	Yes	No	NA	Yes	8/9
Eftekharian et al.   27	Yes	Yes	Yes	No	Yes	NA	Yes	Yes	NA	Yes	7/8
Rejali et al.   26	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	NA	Yes	9/9
Alonso et al.   32	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	NA	Yes	9/9
Al-Shammri et al.   25	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	NA	7/9
Al-Afasy et al.   37	Yes	Yes	Yes	No	Yes	No	Yes	Yes	NA	Yes	7/9
Al Wutayd et al.   24	Yes	Yes	Yes	Yes	Yes	NA	No	Yes	Yes	Yes	8/9
Halawani et al.   23	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	9/10
Mansouri et al.   22	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	10/10
Abdollahpour et al.   35	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	10/10
Maghzi et al.   38	Yes	Yes	Yes	Yes	Yes	NA	Yes	Yes	NA	Yes	8/8
Roudbari et al.   33	No	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Yes	7/10
Mouhieddine et al.   36	Yes	Yes	Yes	Yes	Yes	Yes	NA	Yes	No	Yes	8/9

Q1: Was the sample representative of the target population?

Q2: Were study participants recruited in an appropriate way?

Q3: Was the sample size adequate?

Q4: Were the study subjects and setting described in detail?

Q5: Is the data analysis conducted with sufficient coverage of the identified sample?

Q6: Were objective standard criteria used for measurement of the condition?

Q7: Was the condition measured reliably?

Q8: Was there an appropriate statistical analysis?

Q9: Are all important confounding factors/subgroups/differences identified and accounted for?

Q10: Were subpopulations identified using objective criteria?

NMO-IgG: Neuromyelitis optica immunoglobulin G; NA: Not available